An Observational Case-Control Study to Determine Human Immunodeficiency Virus and Host Factor Influence on Biomarker Distribution and Serodiagnostic Potential in Adult Pulmonary Tuberculosis

Influence of host factors, including human immunodeficiency virus (HIV) co-infection, on the distribution and diagnostic potential of previously evaluated biomarkers of pulmonary tuberculosis (PTB), such as anti-antigen 60 (A60) immunoglobulin (Ig) G, anti-A60 IgA, and C-reactive protein (CRP), remain unclear. Anti-A60 IgG, anti-A60 IgA, and CRP in PTB and non-PTB patient sera (n = 404, including smear-positive/negative, culture-positive (SPCP/SNCP) and HIV+ve/−ve) were measured by enzyme-linked immunoassay and statistically analysed. In multinomial logistic regression, expectoration, chest pain, wasting, and culture count positively associated with CRP (p < 0.001), while smear count positively associated with anti-A60 IgG (p = 0.090). Expectoration and enlarged lymph nodes negatively associated with anti-A60 IgA (p = 0.018). Biomarker distribution and diagnostic potential varied significantly by symptoms and bacilli burden, and across different PTB subpopulations. CRP was correlated poorly with anti-A60 antibodies, while anti-A60 IgA and IgG were correlated in non-tuberculosis (TB) and SPCP patients (p < 0.001). When combined, anti-A60 IgG and CRP best discriminated SPCP/HIV−ve from non-TB (AUC: 0.838, 95% CI: 0.783–0.894), while anti-A60 IgA and CRP performed best in discriminating HIV+ve PTB from non-TB (AUC: 0.687, 95% CI: 0.598–0.777). Combined CRP and anti-A60 antibodies had significantly reduced accuracy in SNCP and SNCP/HIV+ve compared to SPCP/HIV−ve subpopulations. The complex relationships between host factors and biomarkers suggest their limited utility, especially in SNCP/HIV+ve subpopulations, highlighting the importance of examining host response and immune biomarkers across relevant patient subpopulations.

Download Full-text

Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus

Clinical Infectious Diseases ◽

10.1093/cid/ciz765 ◽

2019 ◽

Vol 70 (8) ◽

pp. 1764-1767

Author(s):

Janine M Trevillyan ◽

Carlee Moser ◽

Judith S Currier ◽

Tamer Sallam

Keyword(s):

Human Immunodeficiency Virus ◽

Cardiovascular Risk ◽

High Sensitivity ◽

Myocardial Infarctions ◽

Control Analysis ◽

Retrospective Case ◽

Reactive Protein ◽

Immune Biomarkers ◽

Immunodeficiency Virus ◽

Case Control Analysis

Abstract In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular risk factors, and the CD4/CD8 T-cell ratio, higher lipopolysaccharide-binding protein (LBP) was associated with future myocardial infarctions in hsCRP human immunodeficiency virus (HIV). LBP may be a marker of cardiovascular risk with utility in HIV.

Download Full-text

Massive Hemoptysis in an Immunocompromised Pregnant Woman With Human Immunodeficiency Virus Disease and Active Pulmonary Tuberculosis

The Annals of Thoracic Surgery ◽

10.1016/j.athoracsur.2007.07.005 ◽

2007 ◽

Vol 84 (6) ◽

pp. 2085-2086 ◽

Cited By ~ 4

Author(s):

David F. Blyth ◽

Mahomed A. Soni ◽

Neil F. Moran

Keyword(s):

Human Immunodeficiency Virus ◽

Pregnant Woman ◽

Pulmonary Tuberculosis ◽

Virus Disease ◽

Human Immunodeficiency Virus Disease ◽

Massive Hemoptysis ◽

Active Pulmonary Tuberculosis ◽

Immunodeficiency Virus

Download Full-text

Anti- cyclic citrullinated peptide antibodies in tuberculosis and human immunodeficiency virus

International Journal of Advances in Medicine ◽

10.18203/2349-3933.ijam20201615 ◽

2020 ◽

Vol 7 (5) ◽

pp. 804

Author(s):

Rakesh K. Yadav ◽

Raj K. ◽

Kachnar V. ◽

Manoj K. Mathur ◽

Amitabh D. Shukla

Keyword(s):

Rheumatoid Arthritis ◽

Human Immunodeficiency Virus ◽

Virus Infection ◽

Pulmonary Tuberculosis ◽

Infectious Diseases ◽

Human Immunodeficiency Virus Infection ◽

Extra Pulmonary Tuberculosis ◽

Immunodeficiency Virus ◽

Extra Pulmonary ◽

Citrullinated Peptide

Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been considered very specific for rheumatoid arthritis (RA). Some studies have shown that these antibodies can be positive in infectious diseases like tuberculosis, human immunodeficiency virus infection, etc.Methods: Eighty patients of tuberculosis both pulmonary and extra-pulmonary tuberculosis and thirty patients of human immunodeficiency virus were enrolled in this study from inpatient and outpatient departments from September 2018 to August 2019. Anti-CCP antibody test was done in all the patient by enzyme linked immunosorbent assay.Results: Fifty-three patients were of pulmonary tuberculosis, 27 patients were extra-pulmonary tuberculosis and 30 patients were human immunodeficiency virus infection. Of the 53 cases of pulmonary tuberculosis, 21 (39.6%) cases were positive for anti-CCP antibodies and 32 (60.4%) cases were negative for the same. Of the 27 cases of extra-pulmonary tuberculosis, 3(11.1%) cases were positive for anti-CCP antibodies and 24 (88.9%) cases were negative. Of the 53 patients of pulmonary tuberculosis, 16 were sputum positive and 37 were sputum negative. Of those withsputum positive 9 (56.2%) cases were positive for anti-CCP antibodies and those with sputum negative, 12 (32.4%) cases were positive for anti-CCP antibodies. Of the 30 cases of human immunodeficiency virus, 5 (16.7%) cases were positive for anti-CCP antibodies and 25 (83.3%) cases were negative.Conclusions: Anti-CCP can be positive in cases of infectious diseases like tuberculosis and human immunodeficiency virus. Positivity of anti-CCP antibodies for tuberculosis is more for pulmonary (more for sputum-positive than sputum-negative) than extra-pulmonary tuberculosis. Anti-CCP, thus is not very specific for rheumatoid arthritis.

Download Full-text